{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:56:21Z","timestamp":1793318181307,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"publisher","award":["QUST-2-CPH-2020-16"],"award-info":[{"award-number":["QUST-2-CPH-2020-16"]}],"id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11033-022-07183-w","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T22:44:59Z","timestamp":1643669099000},"page":"2321-2324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin\u2013angiotensin\u2013aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study"],"prefix":"10.1007","volume":"49","author":[{"given":"Diala Alhaj","family":"Moustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roua","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menatallah","family":"Rayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain-Pierre","family":"Gadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Eldassouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Abdulrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6188-1145","authenticated-orcid":false,"given":"Fatima","family":"Mraiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"issue":"6","key":"7183_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.hrtlng.2020.09.002","volume":"49","author":"K Gupta","year":"2020","unstructured":"Gupta K, Kunal S (2020) SGLT-2 inhibitors as cardioprotective agents in COVID-19. Heart Lung 49(6):875\u2013876","journal-title":"Heart Lung"},{"issue":"12","key":"7183_CR2","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.jiph.2020.07.014","volume":"13","author":"H Ejaz","year":"2020","unstructured":"Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE et al (2020) COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health 13(12):1833\u20131839","journal-title":"J Infect Public Health"},{"issue":"12","key":"7183_CR3","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.2337\/dbi20-0032","volume":"69","author":"EL Feldman","year":"2020","unstructured":"Feldman EL, Savelieff MG, Hayek SS, Pennathur S, Kretzler M, Pop-Busui R (2020) COVID-19 and diabetes: a collision and collusion of two diseases. Diabetes 69(12):2549","journal-title":"Diabetes"},{"issue":"11","key":"7183_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845\u2013854","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10166","key":"7183_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RH, Bhatt DL (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet 393(10166):31\u201339","journal-title":"The Lancet"},{"issue":"4","key":"7183_CR6","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/dom.14296","volume":"23","author":"M Kosiborod","year":"2021","unstructured":"Kosiborod M, Berwanger O, Koch G, Martinez F, Mukhtar O, Verma S et al (2021) Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: design and rationale for the DARE-19 study. Diabetes Obes Metab 23(4):886\u2013896","journal-title":"Diabetes Obes Metab"},{"key":"7183_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0547-1","author":"H Zou","year":"2017","unstructured":"Zou H, Zhou B, Xu G (2017) SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/s12933-017-0547-1","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"7183_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"1","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J (2018) Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 1(15):335\u2013346","journal-title":"Redox Biol"},{"issue":"6","key":"7183_CR9","doi-asserted-by":"publisher","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"N Terami","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, Eguchi J, Horiguchi CS, Nishii N, Yamada H, Takei K (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PloS one 9(6):e100777","journal-title":"PloS one"},{"issue":"1","key":"7183_CR10","doi-asserted-by":"publisher","first-page":"E43","DOI":"10.1152\/ajpendo.00219.2020","volume":"319","author":"J Mori","year":"2020","unstructured":"Mori J, Oudit G, Lopaschuk G (2020) SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism. Am J Physiol-Endocrinol Metab 319(1):E43\u2013E47","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"7183_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00836","author":"Z Wehbe","year":"2020","unstructured":"Wehbe Z, Hammoud S, Soudani N, Zaraket H, El-Yazbi A, Eid A (2020) Molecular insights into SARS COV-2 interaction with cardiovascular disease: role of RAAS and MAPK signaling. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2020.00836","journal-title":"Front Pharmacol"},{"issue":"3","key":"7183_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11906-020-1028-6","volume":"22","author":"K Azushima","year":"2020","unstructured":"Azushima K, Morisawa N, Tamura K, Nishiyama A (2020) Recent research advances in renin-angiotensin-aldosterone system receptors. Curr Hypertens Rep 22(3):22","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"7183_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/ijms18051083","volume":"18","author":"D Kawanami","year":"2017","unstructured":"Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T et al (2017) SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci 18(5):1083","journal-title":"Int J Mol Sci"},{"issue":"6","key":"7183_CR14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/cvr\/cvaa078","volume":"116","author":"L Chen","year":"2020","unstructured":"Chen L, Li X, Chen M, Feng Y, Xiong C (2020) The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res 116(6):1097\u20131100","journal-title":"Cardiovasc Res"},{"issue":"7","key":"7183_CR15","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1365-2362.2009.02153.x","volume":"39","author":"GY Oudit","year":"2009","unstructured":"Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, Butany J (2009) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 39(7):618\u2013625","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"7183_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury. Nat Med 11(8):875\u2013879","journal-title":"Nat Med"},{"issue":"5","key":"7183_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/ki.2014.246","volume":"86","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, Johansen OE, Broedl UC, Von Eynatten M, Burns KD (2014) Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86(5):1057\u20131058","journal-title":"Kidney Int"},{"issue":"2","key":"7183_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jphs.2017.10.006","volume":"137","author":"L Li","year":"2018","unstructured":"Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H et al (2018) Effect of a SGLT2 inhibitor on the systemic and intrarenal renin\u2013angiotensin system in subtotally nephrectomized rats. J Pharmacol Sci 137(2):220\u2013223","journal-title":"J Pharmacol Sci"},{"issue":"12","key":"7183_CR19","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","volume":"3","author":"MH Muskiet","year":"2015","unstructured":"Muskiet MH, van Raalte DH, van Bommel EJM, Smits MM, Tonneijck L (2015) Understanding Empa-Reg outcome. Lancet Diabetes Endocrinol 3(12):928\u20139","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7183_CR20","unstructured":"COVID-19, U., (2021).\u00a0Update on the DARE-19 Phase III trial for Farxiga in COVID-19. [online] Astrazeneca.com. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/update-on-farxiga-covid-19-dare-19-phase-iii-trial.html#:~:text=In%20August%202020%2C%20results%20from,and%20without%20T2D%20versus%20placebo. Accessed 9 July 2021."},{"key":"7183_CR21","unstructured":"TCTMD.com. (2021).\u00a0Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients. [online]. https:\/\/www.tctmd.com\/news\/dapagliflozin-no-help-no-harm-hospitalized-covid-19-patients. Accessed 9 July 2021."},{"key":"7183_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.679124","author":"L Zhao","year":"2021","unstructured":"Zhao L, Zhang M, Zhan Z, Qiu M (2021) Does combination therapy with SGLT2 inhibitors and renin\u2013angiotensin system blockers lead to greater reduction in cardiorenal events among patients with type 2 diabetes. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2021.679124","journal-title":"Front Cardiovasc Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07183-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-07183-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-07183-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T07:43:05Z","timestamp":1645515785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-07183-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["7183"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-07183-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"17 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}